This infographic highlights the key advantages of CHO cells and the technologies that are pushing the boundaries of cell ...

Biologic drugs based on recombinant proteins first hit the market with insulin in 1982. They are now one of the fastest-growing sectors of the pharmaceutical industry, with hundreds of proteins ...

macromolecular structure and as therapeutic targets for drug development projects. The major core services are the following: Up-front consultation on experimental design and assistance with ...

The FDA has approved a new drug for a serious heart condition that affects thousands of people. The drug, called Amvuttra ...

By consistently adapting to new regulatory challenges and guidelines, we deliver solutions, whether it comes through recombinant proteins, antibodies, assay kits, GMP-grade reagents, or custom ...

The result puts Scholar Rock out in front of a small group of drugmakers developing myostatin-targeting drugs for SMA, alongside Biohaven's recombinant protein drug taldefegrobep alfa – in the ...

By utilizing Oppenheimer, for instance, Peptone helped with unlocking the therapeutic potential of an orphaned IDP that is in development to become a recombinant protein drug, and addressed the ...

A previously unknown protein in a family of bacteria found in soil and the human gut microbiome has been discovered—which ...

Overview: Kexing Biopharm Co., Ltd. focuses on the research, development, production, and sale of recombinant protein drugs and microbial preparations both in China and internationally ...

The Global Recombinant Chemicals Market is valued at approximately USD 2.9 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 7.8% over the forecast period 2024-2032.